Hypercoagulability and Tissue Factor Gene Upregulation in Hematologic Malignancies

ABSTRACT

Thrombotic complications in patients with hematologic malignancies are as frequent as in those with solid tumors and significantly affect morbidity and mortality. In acute leukemia, thrombosis and bleeding manifestations may occur concomitantly as a part of the same thrombo-hemorrhagic syndrome. In patients with Philadelphia chromosome–negative chronic myeloproliferative disorders (i.e., essential thrombocythemia [ET] and polycythemia vera [PV]), a thrombosis rate as high as 40% has been recorded. A hypercoagulable state is present in virtually all of these patients, even without clinical manifestations. In this review, we focus on the pathogenic mechanisms underlying the hypercoagulable state of these two hematologic malignancies. Although the pathogenesis of hypercoagulability is complex, a central role is played by the fundamental molecular changes of both the leukemic cells and of the progeny arising from the hematopoietic progenitor cells that have undergone clonal rearrangement. These cells overexpress procoagulant factors, as well as adhesion molecules and cytokines capable of inducing procoagulant changes in the vascular wall and stimulating increased cellular interactions. Recent molecular studies in experimental models of human tumors have demonstrated for the first time that oncogene- and repressor gene–mediated neoplastic transformation induces activation of blood coagulation. Similarly, in cells from patients with acute promyelocytic leukemia, the t_15–17 translocation induces hyperexpression of tissue factor (TF) and renders the patient hypercoagulable. Furthermore, in blood cells from patients with PV or ET, the presence of the JAK2V617F mutation translates into activation of hemostasis, with increased expression of platelet-associated TF microparticles and the formation of increased platelet/neutrophil aggregates. Understanding the pathophysiology of hypercoagulability is critical to the design of appropriate measures for intervention in these hematologic disorders to prevent thromboembolic complications.

KEYWORDS

Hypercoagulable state - tissue factor - acute promyelocytic leukemia - essential thrombocythemia - polycythemia vera

REFERENCES

• 1 Barbui T, Finazzi G, Falanga A. The management of bleeding and thrombosis in acute leukemia and chronic myeloproliferative disorders. In: Henderson ES, Lister TA, Greaves MF Leukemia, 7th ed. Philadelphia, PA; Saunders 2001: 363-382
• 2 Falanga A, Rickles F R. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia.  Best Pract Res Clin Haematol. 2003;  16 463-482
• 3 Falanga A, Marchetti M. Thromboembolism in hematologic malignancies. In: Khorana AA, Francis CW Cancer-Associated Thrombosis. New York, NY; Informa Healthcare 2008: 131-149
• 4 Ziegler S, Sperr W R, Knobl P et al.. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis.  Thromb Res. 2005;  115 59-64
• 5 De Stefano V, Sora F, Rossi E et al.. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment.  J Thromb Haemost. 2005;  3 1985-1992
• 6 Barbui T, Finazzi G. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.  Semin Thromb Hemost. 2007;  33 321-329
• 7 Schafer A I. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia.  Blood. 2006;  107 4214-4222
• 8 Michiels J J, Berneman Z, Bockstaele D V, van der Planken M, De Raeve H, Schroyens W. Clinical and laboratory features, pathology of platelet-mediated thrombosis and bleeding complications and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.  Semin Thromb Hemost. 2006;  32 174-207
• 9 Dvorak H F, Rickles F R. Malignancy and hemostasis. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ Hemostasis and Thrombosis, Basic Principles and Clinical Practice. Philadelphia, PA; Lippincott Williams & Wilkins 2006: 851-873
• 10 Rickles F R, Falanga A. Molecular basis for the relationship between thrombosis and cancer.  Thromb Res. 2001;  102 V215-V224
• 11 Boccaccio C, Sabatino G, Medico E et al.. The MET oncogene drives a genetic programme linking cancer to haemostasis.  Nature. 2005;  434 396-400
• 12 Rong Y, Post D E, Pieper R O et al.. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma.  Cancer Res. 2005;  65 1406-1413
• 13 Yu J L, May L, Lhotak V et al.. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis.  Blood. 2005;  105 1734-1741
• 14 Falanga A, Marchetti M, Vignoli A et al.. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte and plasma hemostatic and inflammatory molecules.  Exp Hematol. 2007;  35 702-711
• 15 Tallman M S, Lefebvre P, Baine R M et al.. Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia.  J Thromb Haemost. 2004;  2 1341-1350
• 16 Falanga A, Iacoviello L, Evangelista V et al.. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocitic leukemia given all-trans-retinoic acid.  Blood. 1995;  86 1072-1084
• 17 Dombret H, Scrobohaci M L, Daniel M T et al.. In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy.  Leukemia. 1995;  9 19-24
• 18 Falanga A, Marchetti M, Evangelista V et al.. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.  Blood. 2000;  96 4261-4266
• 19 Friedenberg W R, Roberts R C, David D E. Relationship of thrombohemorrhagic complications to endothelial cell function in patients with chronic myeloproliferative disorders.  Am J Hematol. 1992;  40 283-289
• 20 Bellucci S, Ignatova E, Jaillet N, Boffa M C. Platelet hyperactivation in patients with essential thrombocythemia is not associated with vascular endothelial cell damage as judged by the level of plasma thrombomodulin, protein S, PAI-1, tPA and vWF.  Thromb Haemost. 1993;  70 736-742
• 21 Landolfi R, Ciabattoni G, Patrignani P et al.. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo.  Blood. 1992;  80 1965-1971
• 22 Elliott M A, Tefferi A. Thrombosis and haemorrage in polycythemia vera and essential thrombocythemia.  Br J Haematol. 2005;  128 275-290
• 23 Burgaleta C, Gonzalez N, Cesar J. Increased CD11/18 expression and altered metabolic activity in polymorphonuclear leukocytes from patients with polycythemia vera and essential thrombocythemia.  Acta Haematol. 2002;  108 23-28
• 24 Falanga A, Marchetti M, Evangelista V et al.. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.  Blood. 2000;  96 4261-4266
• 25 Kwaan H C, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities.  Semin Thromb Hemost. 2003;  29 451-458
• 26 Yedgar S, Koshkaryev A, Barshtein G. The red blood cell in vascular occlusion.  Pathophysiol Haemost Thromb. 2002;  32 263-268
• 27 Valles J, Santos M T, Aznar J et al.. Platelet-erythrocyte interactions enhance alpha (IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo.  Blood. 2002;  99 3978-3984
• 28 Pearson M J, Lipowsky H H. Influence of erythrocyte aggregation on leukocyte margination in postcapillary venules of rat mesentery.  Am J Physiol Heart Circ Physiol. 2000;  279 M1460-1471
• 29 Jensen M K, de Nully Brown P, Lund B V, Nielsen O, Hasselbalch H C. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders.  Br J Haematol. 2000;  110 116-124
• 30 Li N, Goodall A H, Hjemdahl P. A sensitive flow cytometric assay for circulating platelet-leukocyte aggregates.  Br J Haematol. 1997;  99 808-816
• 31 Villmow T, Kemkes-Matthes B, Matzdorff A C. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes.  Thromb Res. 2002;  108 139-145
• 32 Alvarez-Larràn A, Garcìa-Pagàn J C, Abraldes J G et al.. Increased CD11b neuthrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera.  Br J Haematol. 2004;  124 329-335
• 33 Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocytemia and polycythemia vera.  Exp Hematol. 2005;  33 523-530
• 34 Celi A, Pellegrini G, Lorenzet R et al.. P-selectin induces the expression of tissue factor on monocytes.  Proc Natl Acad Sci U S A. 1994;  91 8767-8771
• 35 Kralovics R, Passamonti F, Buser A S, Teo S S, Tiedt R, Passweg J R. A gain-function mutation of JAK2 in myeloproliferative disorders.  N Engl J Med. 2005;  352 1779-1790
• 36 Wolanskyj A P, Schwager S M, McClure R F, Larson D R, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors.  Mayo Clin Proc. 2006;  81 159-166
• 37 Campbell P J, Scott L M, Buck G et al.. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.  Lancet. 2005;  366 1945-1953
• 38 Muller I, Klocke A, Alex M et al.. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets.  FASEB J. 2003;  17 476-478
• 39 Falati S, Liu Q, Gross P et al.. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin.  J Exp Med. 2003;  197 1585-1598
• 40 Myers D D, Hawley A E, Farris D M et al.. P-selectin and leukocyte microparticles are associated with venous thrombogenesis.  J Vasc Surg. 2003;  38 1075-1089
• 41 Maugeri N, Giordano G, Petrilli M P et al.. Inibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?.  J Thromb Haemost. 2006;  4 2593-2598
• 42 Shoji M, Hancock W W, Abe K et al.. Activation of coagulation and angiogenesis in cancer. Immunohistochemical localization in situ of clotting proteins and VEGF in human cancers.  Am J Pathol. 1998;  152 399-411
• 43 Lyman G H, Khorana A A, Falanga A et al.. American society of clinical oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.  J Clin Oncol. 2007;  25 5490-5505
• 44 Kuderer N M, Khorana A, Lyman G H, Francis C W. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications.  Cancer. 2007;  110 1149-1161